The company's proprietary technologies expand the utility of clinically-validated AAV vectors to address a wider range of diseases caused by mutations in large genes and autosomal dominant inheritance patterns. Limelight Bio's focus is on severe retinal, hematologic/metabolic, neurologic, and hearing loss diseases. The company was founded in 2016 and is headquartered in Philadelphia, Pennsylvania.